Xolair (omalizumab)

DRUG6 trials

Sponsors

Genentech, Inc., Massachusetts General Hospital, Taizhou Mabtech Pharmaceutical Co.,Ltd

Conditions

AllergyAsthmaChronic RhinosinusitisHealthy Volunteers (HV)Nasal Polyps

Phase 1

Compare the PK, Safety, and Immunogenicity of Process-Changed CMAB007 and Xolair in Healthy Adult Male Subjects

CompletedNCT07246252

Taizhou Mabtech Pharmaceutical Co.,LtdHealthy Volunteers (HV)

Start: 2024-03-28End: 2024-12-02Updated: 2025-11-24

Phase 2

A Safety and Efficacy Study of Xolair in Peanut Allergy

TerminatedNCT00086606

Genentech, Inc.Allergy

Start: 2004-06-30End: 2006-04-30Target: 150Updated: 2013-01-21

Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis

CompletedNCT01066104

Massachusetts General HospitalChronic Rhinosinusitis, Nasal Polyps

Start: 2009-12-31End: 2015-07-31Updated: 2017-06-14

Phase 3

A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma

CompletedNCT00109200

Genentech, Inc.Asthma

Start: 2003-05-31End: 2003-09-30Updated: 2013-06-21

An Extension Study of Xolair in Moderate to Severe, Persistent Asthma Patients Who Completed Study Q2143g

CompletedNCT00109187

Genentech, Inc.Asthma

Start: 2002-06-30End: 2003-04-30Updated: 2013-06-21

A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)

CompletedNCT00401596

Genentech, Inc.Asthma

Start: 2000-07-31End: 2002-07-31Target: 1899Updated: 2014-03-19

Related Papers

Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma.

2019-11-2232 citations